A Phase III Study of the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (APECS)
What is the APECS Study?
Subjects with amnestic mild cognitive impairment will receive verubecestat or placebo given orally for 104 weeks with the option to continue in the second part of the study, which is long-term extension phase (260 weeks). Study visits are roughly every 3 months and consist of cognitive assessments, laboratory procedures, and study medication dispensing.
What is the Purpose of APECS?
APECS is a two part study to assess the efficacy and safety of an investigational medication, verubecestat, in early Alzheimer's Disease. Verubecestat is thought to inhibit the formation of beta-amyloid proteins. Beta-amyloid plaques are believed to be a leading component to the progression of Alzheimer's Disease.
Men and women ages 50-85 years old with a diagnosis of prodromal Alzheimer's Disease. There are other eligibility criteria you must meet in order to participate.
Please review the APECS Poster
and Study Facts Sheet
for additional details about the trial.
If you are interested in learning more about the APECS study, please call (401) 455-6403 or send an e-mail to: firstname.lastname@example.org. Ask about the “APECS study.”
For information on other current research studies at Butler Hospital please click here.